AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy
- 1 May 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 65 (5) , 1073-1081
Abstract
The hemodynamic and nonhemodynamic effects of angiotensin II on diabetic complications are considered to be primarily mediated by the angiotensin II type 1 receptor subtype. However, its biological and functional effect mediated through the angiotensin II type 2 receptor subtype is still unclear. Activation of the angiotensin II type 2 receptors has been postulated to oppose angiotensin II type 1 receptor–mediated actions and thus attenuate fibrosis. This study aimed to elucidate the reno-protective role of the novel selective angiotensin II type 2 receptor agonist, Compound 21, in an experimental model of type 1 diabetic nephropathy. Compound 21 treatment significantly attenuated diabetes mellitus–induced elevated levels of cystatin C, albuminuria, mesangial expansion, and glomerulosclerosis in diabetic mice. Moreover, Compound 21 markedly inhibited the expression of various proteins implicated in oxidative stress, inflammation, and fibrosis, in association with decreased extracellular matrix production. These findings demonstrate that monotherapy of Compound 21 is protective against the progression of experimental diabetic nephropathy by inhibiting renal oxidative stress, inflammation, and fibrosis.Keywords
This publication has 43 references indexed in Scilit:
- Angiotensin II Type II Receptor Deficiency Accelerates the Development of Nephropathy in Type I Diabetes via Oxidative Stress and ACE2Experimental Diabetes Research, 2011
- Angiotensin II as a Morphogenic Cytokine Stimulating Renal FibrogenesisJournal of the American Society of Nephrology, 2011
- Role of the AT2 receptor in modulating the angiotensin II contractile response of the uterine artery at mid-gestationJournal of the Renin-Angiotensin-Aldosterone System, 2011
- Angiotensin AT 2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular HypertensionHypertension, 2011
- The angiotensin II type 2 receptor and the kidneyJournal of the Renin-Angiotensin-Aldosterone System, 2009
- AT2 receptors: Functional relevance in cardiovascular diseasePharmacology & Therapeutics, 2008
- Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent HypertensionThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Cardiovascular and Renal Regulation by the Angiotensin Type 2 ReceptorHypertension, 2005
- Angiotensin AT2 receptors: cardiovascular hope or hype?British Journal of Pharmacology, 2003
- Angiotensin II and growth factors in the pathogenesis of diabetic nephropathyKidney International, 2002